Novo Expects a CagriSema Verdict by Year-End. It Already Lost to Zepbound

Share

Novo Nordisk expects the FDA to decide on CagriSema, its weekly combination of semaglutide and the amylin analog cagrilintide, before the end of 2026. The company confirmed the anticipated fourth-quarter decision alongside its November 4 financial results and is preparing for a U.S. launch in early 2027, subject to approval. If cleared, CagriSema could become the first obesity treatment to combine a GLP-1 receptor agonist with an amylin analog in one injection. It would also arrive having failed to match Eli Lilly’s Zepbound in an 84-week head-to-head trial.

That tension defines the drug’s position. CagriSema has delivered substantial weight loss across its clinical program, including results exceeding 20% under some trial analyses. But the market has moved while Novo developed it. Zepbound is established, oral GLP-1 drugs are expanding treatment choices, and Novo is already advancing another molecule that activates both GLP-1 and amylin pathways. The FDA will decide whether CagriSema can be marketed for its proposed indication. That is a different question from whether it can recover ground for Novo.

What CagriSema Is

CagriSema combines two peptides in a single weekly injection. Semaglutide is the GLP-1 receptor agonist already used in Wegovy and Ozempic, an engineered peptide whose long half-life comes partly from albumin binding. Cagrilintide is a long-acting analog of amylin, a hormone released by the pancreas alongside insulin. Amylin participates in appetite regulation and signals fullness, while the GLP-1 pathway also influences appetite, food intake and glucose control.

The idea is to activate complementary biological pathways and produce more weight loss than either peptide alone. Cagrilintide also acts at calcitonin receptors, making its pharmacology broader than a simple second GLP-1 signal.

Novo submitted CagriSema’s new drug application to the FDA on December 18, 2025, seeking approval for use alongside diet and physical activity in adults with obesity, or overweight with at least one weight-related condition. Its pivotal application rests primarily on the REDEFINE 1 and REDEFINE 2 trials. As of November 17, 2026, CagriSema remains investigational, and Novo has publicly identified the fourth quarter as the expected decision window without announcing an exact FDA action date.

CagriSema could be the first GLP-1 and amylin obesity combination on the market. Its most important direct comparison has already gone against it.

The Trial Record Behind the FDA Application

The core obesity evidence comes from REDEFINE 1, a randomized, double-blind, 68-week trial in 3,417 adults with obesity or overweight and an obesity-related complication, without type 2 diabetes. Participants received CagriSema, semaglutide alone, cagrilintide alone or placebo, alongside lifestyle intervention.

The distinction between the trial’s statistical analyses matters. Under the hypothetical scenario in which everyone remained on assigned treatment, CagriSema produced an estimated 22.7% average reduction in body weight, versus 2.3% with placebo. Under the treatment-policy analysis, which accounts for treatment discontinuation and other treatment changes, the corresponding figures were 20.4% and 3.0%. Both showed a substantial treatment effect, but they answer different questions about how the drug performs.

In REDEFINE 2, which studied adults with type 2 diabetes, CagriSema produced an estimated 13.7% weight reduction at 68 weeks versus 3.4% with placebo in the treatment-policy analysis reported in the New England Journal of Medicine. Those results were lower than in REDEFINE 1, consistent with the difficulty of achieving comparable weight loss in people with diabetes.

Another trial, REIMAGINE 2, tested CagriSema against its individual components in adults with type 2 diabetes. At 68 weeks, CagriSema 2.4/2.4 mg reduced HbA1c by 1.91 percentage points and body weight by 14.2% in the efficacy analysis, compared with 1.75 points and 10.2% for semaglutide 2.4 mg alone. The differences were statistically significant, providing evidence that adding cagrilintide contributes to the treatment effect.

In September 2026, Novo also announced REIMAGINE 5, a 60-week trial in which CagriSema 1.0/1.0 mg produced 12.4% weight loss, versus 9.1% with tirzepatide 5 mg, while meeting non-inferiority for HbA1c reduction. That was a result against tirzepatide’s lowest maintenance dose, not the 15 mg dose used in the major obesity head-to-head trial. The two comparisons should not be treated as contradictory or interchangeable.

The Head-to-Head Loss Against Zepbound

The result that defines CagriSema’s commercial problem came on February 23, 2026. In REDEFINE 4, an 84-week, open-label phase 3 study involving 809 randomized adults with obesity and at least one weight-related condition, Novo compared CagriSema 2.4/2.4 mg directly with tirzepatide 15 mg, the active ingredient in Eli Lilly’s Zepbound.

Under the treatment-regimen analysis, average weight loss was 20.2% with CagriSema and 23.6% with tirzepatide. Assuming full adherence, the figures were 23.0% and 25.5%. The study failed its primary objective of showing that CagriSema was non-inferior to tirzepatide for weight loss. Novo’s shares fell sharply after the announcement, and BioPharma Dive reported analysts questioning whether CagriSema could support premium commercial positioning.

Non-inferiority is a specific statistical test, not simply a comparison of two averages. The failure means the trial did not establish that CagriSema was sufficiently close to tirzepatide within its prespecified margin. The observed results also favored tirzepatide. That does not cancel CagriSema’s placebo-controlled efficacy, but it does complicate any claim that adding amylin necessarily makes a product more effective than the best established dual-agonist competitor.

Twenty percent weight loss would have been extraordinary in 2021. In 2026, it is also a question of comparative efficacy and price.

Novo’s response has been to emphasize the absolute benefit, dosing flexibility and future development of the combination. Its research leadership has argued that the drug could still offer meaningful treatment value. That argument is commercially plausible, but the February study makes it harder to present CagriSema as an uncomplicated successor to Wegovy.

New November Data Strengthen the Case, With Limits

Two announcements at ObesityWeek 2026 added evidence after Novo’s November 4 financial update. On November 14, the company presented full results from REDEFINE 9, a 68-week phase 3 trial testing lower CagriSema doses in 309 adults with obesity or overweight. The results were simultaneously published in The Lancet Diabetes & Endocrinology.

In the full-adherence analysis, the 1.7/1.7 mg dose produced 20.7% estimated weight loss, while the 1.0/1.0 mg dose produced 21.0%, compared with 2.0% for placebo. In the treatment-regimen analysis, the corresponding losses were 19.4% and 18.6%, versus 4.6% for placebo. The study was not powered to establish a difference between the two active doses, so their similar results should not be taken as proof that the lower dose is equally effective.

On November 15, Novo presented two post hoc analyses from REDEFINE 1. In one, participants who had lost at least 5% of their starting weight by week eight showed an observed mean weight reduction of 25.4% at week 68, compared with 17.8% among delayed responders. Another analysis found meaningful improvements in patient-reported physical function among 73.1% of CagriSema participants versus 49.1% on placebo under the efficacy estimand.

Those are useful additional findings, but the early-responder comparison is exploratory. The groups were defined after treatment began, not independently randomized to different treatments. Their outcomes cannot replace the average result for the overall trial population or establish which patients will respond best before treatment.

The November results give Novo more to discuss with prescribers, particularly around dose flexibility and patients’ reported functioning. They do not reverse the REDEFINE 4 result against tirzepatide 15 mg.

What Approval Would and Would Not Settle

An approval would mark a significant milestone for amylin-based obesity medicine and provide clinical validation for a combination approach that other manufacturers are also pursuing. Lilly has advanced eloralintide, and AbbVie is developing ABBV-295, a long-acting amylin candidate. The commercial question is not whether amylin can contribute to weight reduction, but which products can turn that mechanism into a tolerable, durable and competitively priced treatment.

The adverse-event record matters here. In REDEFINE 1, gastrointestinal events affected 79.6% of participants assigned to CagriSema versus 39.9% receiving placebo, according to Novo. Nausea, constipation and vomiting were common. Most events were mild to moderate, but approximately 5.9% of participants in the CagriSema arm discontinued treatment because of adverse events. An FDA approval would establish an acceptable benefit-risk balance for the approved indication, not guarantee that every patient can tolerate or continue the drug.

Prescribers would still have to weigh individual treatment history, tolerability, response, access and cost. A product that falls short of a competitor on average weight loss may still have a place in clinical care, but demonstrating that place requires more than a strong comparison with placebo.

Another unresolved question is body composition. Adding amylin has prompted interest in whether different hormonal pathways could change the balance between fat loss and lean-tissue loss, but a reliable muscle-preservation advantage over competing drugs has not been established. Longer-term safety, treatment persistence and cardiovascular outcomes will also matter beyond the initial weight-loss numbers.

There is a financial decision too. In Novo’s third quarter, adjusted injectable Wegovy sales fell 2% at constant exchange rates, while Ozempic’s adjusted sales fell 5%. Its Wegovy pill generated DKK 5.4 billion in quarterly sales, showing that the company is already shifting toward a wider mix of formulations and delivery methods. CagriSema would enter that portfolio as a two-peptide injection competing for patients, prescriptions and reimbursement against an established rival.

The Verdict Beyond the FDA

Novo has another complication of its own making. The company is advancing zenagamtide, formerly known as amycretin, a single peptide designed to activate GLP-1, amylin and calcitonin receptors. Its phase 3 program is underway, with development covering both oral and injectable approaches. If that molecule succeeds, CagriSema could become an intermediate product rather than the company’s final answer to combination obesity therapy.

For now, three milestones are worth watching. The first is the expected FDA decision before the end of 2026. The second is Novo’s planned early-2027 U.S. launch, assuming approval. The third is the REDEFINE 11 readout expected in the first half of 2027, which could clarify the weight-loss potential of CagriSema under a longer treatment schedule.

The FDA will assess CagriSema’s evidence for the indication under review. The market will ask a different question: why choose it when tirzepatide produced greater average weight loss in the direct comparison?

Neither question can be answered by a single percentage. CagriSema has shown that combining GLP-1 and amylin biology can produce substantial weight loss. What it has not yet shown is that the combination can displace Zepbound. The next regulatory decision could put the drug on pharmacy shelves. The years after that will determine whether second place is commercially enough.

Sources

  1. Novo Nordisk — Third-Quarter 2026 Financial Results and Pipeline Update. November 4, 2026.
  2. Novo Nordisk — Novo Nordisk Files for FDA Approval of CagriSema. December 18, 2025.
  3. New England Journal of Medicine — Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. REDEFINE 1, June 22, 2025.
  4. New England Journal of Medicine — Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. REDEFINE 2, June 22, 2025.
  5. Novo Nordisk — CagriSema Demonstrated 23% Weight Loss in REDEFINE 4; Primary Endpoint Not Achieved. February 23, 2026.
  6. BioPharma Dive — Novo’s Next-Gen Obesity Shot Fails to Match Lilly Drug in Head-to-Head Study. February 23, 2026.
  7. Novo Nordisk — CagriSema Phase 3 REIMAGINE Results Presented at ADA 2026. June 7, 2026.
  8. Novo Nordisk — REIMAGINE 5 and REDEFINE 9 Topline Results. September 21, 2026.
  9. Novo Nordisk — REDEFINE 9 Full Results Presented at ObesityWeek 2026 and Published in The Lancet Diabetes & Endocrinology. November 14, 2026.
  10. Novo Nordisk — CagriSema Early-Responder and Patient-Reported Outcome Analyses. November 15, 2026.

Read more

Local News